Skip to main content
AAN.com

Abstract

Background and Objectives

Traumatic brain injury (TBI) may be a chronic condition carrying risk of future sequelae; few prospective studies examine long-term postinjury outcomes. We examined the prevalence of functional, cognitive, and psychiatric change outcomes from 1 to 7 years postinjury.

Methods

Transforming Research and Clinical Knowledge in TBI LONG (TRACK-TBI LONG) participants were prospectively enrolled within 24 hours of injury and followed up to 1 year postinjury; a subset participated in long-term follow-up from 2 to 7 years postinjury. Reliable change thresholds for the Brief Test of Adult Cognition by Telephone General Composite (cognition) and Brief Symptom Inventory (BSI)–18 (psychiatric) were derived from orthopedic trauma controls (OTCs). Multiple assessments were completed (postinjury baseline assessment and 2 or 3 visits 2–7 years postinjury) within a sample subset. Change was assessed for functional outcome (Glasgow Outcome Scale–Extended [GOSE]) and self-report/informant report of decline. Prevalence ratios for outcomes classified as stable, improved, and declined were reported individually and collectively. The Fisher exact test and log-binomial regression models examined factors associated with decline and improvement.

Results

Of the sample (N = 1,264; mild TBI [mTBI], Glasgow Coma Scale [GCS] 13–15, n = 917; moderate-to-severe TBI [msTBI], GCS 3–12, n = 193; or OTC n = 154), “stable” was the most prevalent outcome. Functional outcome showed the highest rates of decline, regardless of TBI severity (mild = 29%; moderate/severe = 23%). When measures were collectively considered, rates of decline included mTBI (21%), msTBI (26%), and OTC (15%). Age and preinjury employment status were associated with functional decline (per 10 years; relative risk [RR] 1.16, 95% CI 1.07–1.25, p < 0.001; higher in retired/disabled/not working vs full-time/part-time; RR 1.81, 95% CI 1.33–2.45, respectively) in the mTBI group. Improvement in functional recovery 2–7 years postinjury was associated with higher BSI scores (per 5 points; RR 1.11, 95% CI 1.04–1.18, p = 0.002) and GOSE score of 5–7 (GOSE = 8 as reference; RR 2.64, 95% CI 1.75–3.97, p < 0.001). Higher BSI scores and identifying as Black (RR 2.28, 95% CI 1.59–3.25, p < 0.001) were associated with a greater likelihood of improved psychiatric symptoms in mTBI (RR 1.21, 95% CI 1.14–1.29, p < 0.001). A greater likelihood of cognitive improvement was observed among those with higher educational attainment in msTBI (per 4 years; RR 2.61, 95% CI 1.43–4.79, p = 0.002).

Discussion

Function across domains at 1-year postinjury, a common recovery benchmark, undergoes change across the subsequent 6 years. Results support consideration of TBI as a chronic evolving condition and suggest continued monitoring, rehabilitation, and support is required to optimize long-term independence and quality of life.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Lj C, Jd C, Pm P, et al. Prognosis for mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med. 2004;43(suppl):84-105.
2.
Pagulayan KF, Temkin NR, Machamer J, Dikmen SS. A longitudinal study of health-related quality of life after traumatic brain injury. Arch Phys Med Rehabil. 2006;87(5):611-618.
3.
Masel BE, DeWitt DS. Traumatic brain injury: a disease process, not an event. J Neurotrauma. 2010;27(8):1529-1540.
4.
Izzy S, Chen PM, Tahir Z, et al. Association of traumatic brain injury with the risk of developing chronic cardiovascular, endocrine, neurological, and psychiatric disorders. JAMA Netw Open. 2022;5(4):e229478.
5.
Corrigan JD, Hammond FM. Traumatic brain injury as a chronic health condition. Arch Phys Med Rehabil. 2013;94(6):1199-1201.
6.
McInnes K, Friesen CL, MacKenzie DE, Westwood DA, Boe SG. Mild traumatic brain injury (mTBI) and chronic cognitive impairment: a scoping review. PLoS One. 2017;12(4):e0174847.
7.
Corrigan JD, Cuthbert JP, Harrison-Felix C, et al. US population estimates of health and social outcomes 5 years after rehabilitation for traumatic brain injury. J Head Trauma Rehabil. 2014;29(6):E1.
8.
Kumar RG, Ketchum JM, Corrigan JD, Hammond FM, Sevigny M, Dams-O'Connor K. The longitudinal effects of comorbid health burden on functional outcomes for adults with moderate to severe traumatic brain injury. J Head Trauma Rehabil. 2020;35(4):E372.
9.
Hammond FM, Grattan KD, Sasser H, et al. Five years after traumatic brain injury: a study of individual outcomes and predictors of change in function. Neurorehabilitation. 2004;19(1):25-35.
10.
Nelson LD, Temkin NR, Dikmen S, et al. Recovery after mild traumatic brain injury in patients presenting to US level I trauma centers: a transforming research and clinical knowledge in traumatic brain injury (TRACK-TBI) study. JAMA Neurol. 2019;76(9):1049-1059.
11.
McCrea MA, Giacino JT, Barber J, et al. Functional outcomes over the first year after moderate to severe traumatic brain injury in the prospective, longitudinal TRACK-TBI study. JAMA Neurol. 2021;78(8):982-992.
12.
Traumatic Brain Injury: A Roadmap for Accelerating Progress. National Academies Press; 2022.
13.
Kay T, Harrington DE, Adams R, et al. Definition of mild traumatic brain injury. J Head Trauma Rehabil. 1993;8(3):86-87.
14.
Silverberg ND, Iverson GL; ACRM Mild TBI Definition Expert Consensus Group and the ACRM Brain Injury Special Interest Group Mild TBI Task Force. Expert panel survey to update the American Congress of Rehabilitation Medicine definition of mild traumatic brain injury. Arch Phys Med Rehabil. 2021;102(1):76-86.
15.
Hughes ML, Agrigoroaei S, Jeon M, Bruzzese M, Lachman ME. Change in cognitive performance from midlife into old age: findings from the Midlife in the United States (MIDUS) study. J Int Neuropsychol Soc. 2018;24(8):805-820.
16.
Lachman ME, Agrigoroaei S, Tun PA, Weaver SL. Monitoring cognitive functioning: psychometric properties of the brief test of adult cognition by telephone. Assessment. 2014;21(4):404-417.
17.
DiBlasio CA, Sima A, Kumar RG, et al. Research letter: performance of the brief test of adult cognition by telephone in a national sample. J Head Trauma Rehabil. 2021;36(4):E233.
18.
Nelson LD, Barber JK, Temkin NR, et al. Validity of the brief test of adult cognition by telephone in level 1 trauma center patients six months post-traumatic brain injury: a TRACK-TBI study. J Neurotrauma. 2021;38(8):1048-1059.
19.
Wilson JT, Pettigrew LE, Teasdale GM. Structured interviews for the Glasgow Outcome Scale and the Extended Glasgow Outcome Scale: guidelines for their use. J Neurotrauma. 1998;15(8):573-585.
20.
Wilson L, Boase K, Nelson LD, et al. A manual for the Glasgow Outcome Scale-Extended interview. J Neurotrauma. 2021;38(17):2435-2446.
21.
Derogatis L. Brief Symptom Inventory 18 (BSI-18): Administration, Scoring, and Procedures Manual. Pearson; 2001.
22.
Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57(1):289-300.
23.
Griffin BA, Ridgeway G, Morral AR, et al. Toolkit for Weighting and Analysis of Nonequivalent Groups (TWANG). RAND Corporation; 2014. Accessed October 9, 2022 rand.org/statistics/twang.
24.
Gao S, Kumar RG, Wisniewski SR, Fabio A. Disparities in health care utilization of adults with traumatic brain injuries are related to insurance, race, and ethnicity: a systematic review. J Head Trauma Rehabil. 2018;33(3):E40-E50.
25.
Hammond FM, Malec JF, Corrigan JD, et al. Patterns of functional change five to ten years after moderate-severe traumatic brain injury. J Neurotrauma. 2021;38(11):1526-1534.
26.
Hammond FM, Perkins SM, Corrigan JD, et al. Functional change from five to fifteen years after traumatic brain injury. J Neurotrauma. 2021;38(7):858-869.
27.
Wilson L, Horton L, Kunzmann K, et al. Understanding the relationship between cognitive performance and function in daily life after traumatic brain injury. J Neurol Neurosurg Psychiatry. 2021;92(4):407-417.
28.
Malec JF, Ketchum JM, Hammond FM, et al. Longitudinal effects of medical comorbidities on functional outcome and life satisfaction after traumatic brain injury: an individual growth curve analysis of NIDILRR traumatic brain injury model system data. J Head Trauma Rehabil. 2019;34(5):E24.
29.
Mikolić A, van Klaveren D, Groeniger JO, et al. Differences between men and women in treatment and outcome after traumatic brain injury. J Neurotrauma. 2021;38(2):235-251.
30.
Starkey NJ, Duffy B, Jones K, et al. Sex differences in outcomes from mild traumatic brain injury eight years post-injury. PLoS One. 2022;17(5):e0269101.
31.
Dams-O'Connor K, Ketchum JM, Cuthbert JP, et al. Functional outcome trajectories following inpatient rehabilitation for TBI in the United States: a NIDILRR TBIMS and CDC Interagency Collaboration. J Head Trauma Rehabil. 2020;35(2):127-139.
32.
Mosenthal AC, Lavery RF, Addis M, et al. Isolated traumatic brain injury: age is an independent predictor of mortality and early outcome. J Trauma Acute Care Surg. 2002;52(5):907-911.
33.
Susman M, DiRusso SM, Sullivan T, et al. Traumatic brain injury in the elderly: increased mortality and worse functional outcome at discharge despite lower injury severity. J Trauma Acute Care Surg. 2002;53(2):219-224.
34.
Gardner RC, Dams-O'Connor K, Morrissey MR, Manley GT. Geriatric traumatic brain injury: epidemiology, outcomes, knowledge gaps, and future directions. J Neurotrauma. 2018;35(7):889-906.
35.
van der Vlegel M, Mikolić A, Lee Hee Q, et al. Health care utilization and outcomes in older adults after traumatic brain injury: a CENTER-TBI study. Injury. 2022;53(8):2774-2782.
36.
Theadom A, Parag V, Dowell T, et al. Persistent problems 1 year after mild traumatic brain injury: a longitudinal population study in New Zealand. Br J Gen Pract. 2016;66(642):e16-e23.
37.
Losoi H, Silverberg ND, Wäljas M, et al. Recovery from mild traumatic brain injury in previously healthy adults. J Neurotrauma. 2016;33(8):766-776.
38.
Wickwire EM, Albrecht JS, Capaldi VF II, et al. Trajectories of insomnia in adults after traumatic brain injury. JAMA Netw Open. 2022;5(1):e2145310.
39.
Stein MB, Jain S, Giacino JT, et al. Risk of posttraumatic stress disorder and major depression in civilian patients after mild traumatic brain injury: a TRACK-TBI study. JAMA Psychiatry. 2019;76(3):249-258.
40.
Zajacova A, Lawrence EM. The relationship between education and health: reducing disparities through a contextual approach. Annu Rev Public Health. 2018;39:273-289.
41.
Shin M, Sohn MK, Lee J, et al. Effect of cognitive reserve on risk of cognitive impairment and recovery after stroke. Stroke. 2020;51(1):99-107.
42.
Thow ME, Summers MJ, Saunders NL, Summers JJ, Ritchie K, Vickers JC. Further education improves cognitive reserve and triggers improvement in selective cognitive functions in older adults: the Tasmanian Healthy Brain Project. Alzheimers Dement. 2018;10:22-30.
43.
Hicks AJ, Spitz G, Rowe CC, Roberts CM, McKenzie DP, Ponsford JL. Does cognitive decline occur decades after moderate to severe traumatic brain injury? A prospective controlled study. Neuropsychol Rehabil. 2022;32(7):1530-1549.

Information & Authors

Information

Published In

Neurology®
Volume 101Number 7August 15, 2023
Pages: e740-e753
PubMed: 37344231

Publication History

Received: December 2, 2022
Accepted: April 21, 2023
Published online: June 21, 2023
Published in print: August 15, 2023

Permissions

Request permissions for this article.

Disclosure

B.L. Brett reports grants from the National Institute on Aging and National Institute of Neurological Disorders and Stroke (NINDS). N. Temkin reported receiving grants from the US Department of Defense (DoD) and NIH/NINDS during the conduct of the study. M. Stein reported receiving grants from the NIH subcontract from University of California, San Francisco (UCSF) during the conduct of the study; other from Oxeia Biopharmaceuticals Stock options outside the submitted work. J.T. Giacino reported receiving support from the UCSF subcontract during the conduct of the study. M.A. McCrea reported receiving grants from the UCSF, Research subaward to Medical College of Wisconsin during the conduct of the study. Y.G. Bodien reported receiving grants from NINDS, DoD, James S. McDonnell Foundation, Tiny Blue Dot, and National Institute on Disability, Independent Living, and Rehabilitation Research during the conduct of the study. J. Corrigan reported receiving grants from the NIH during the conduct of the study. R. Diaz-Arrastia reported receiving grants from the NIH and DoD during the conduct of the study; owing stock in BrainBox and Nia Therapeutics; and personal fees from Pinteon Therapeutics, MesoScale Discoveries, and Ischemix outside the submitted work. L. Nelson reported receiving grants from the NINDS, Centers for Disease Control and Prevention, DoD, and Advancing a Healthier Wisconsin outside the submitted work. Go to Neurology.org/N for full disclosures.

Study Funding

The study was funded by National Institute of Neurological Disorders and Stroke (NINDS) grant number U01 NS086090 and the National Football League (NFL) Scientific Advisory Board. The study also received funding from (CDMRP) TBI Endpoints Development (TED) Initiative (grant number W81XWH-14-2-0176). B.L. Brett's effort was also supported by National Institute on Aging grant number K23 AG073528-01 and NINDS grant number L30 NS113158-02. L. Nelson's effort was also supported by NINDS grant numberR01 NS110856. The manuscript's contents are solely the responsibility of the authors; they do not necessarily represent the official views of the NIH and are not necessarily endorsed by the US Department of Defense or NFL.

Authors

Affiliations & Disclosures

From the Medical College of Wisconsin (B.L.B., M.A.M., L.D.N.), Milwaukee; University of Washington (N.T., J.K.B.), Seattle; University of Pittsburgh Medical Center (D.O.O.), PA; University of California San Diego (M.S.), La Jolla; Massachusetts General Hospital and Harvard Medical School (Y.G.B., J.T.G.), Boston; The Ohio State University Wexner Medical Center (J.C.), Columbus; University of Pennsylvania (R.D.-A.), Philadelphia; and University of California, San Francisco (G.T.M.).
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Sports Neuropsychology Society, honorarium and travel <br>reimbursement for conference presentation/speaker.
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) National Institutes of Health, National Institute on <br>Aging, Career Developmental Award # K23 AG073528-01, <br>principle investigator, year 2 of 5 year award; (2) National <br>Institute of Neurological Disorders and Stroke, grant # L30 <br>NS113158-02, principle investigator, year 2 of 2.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Nancy Temkin, PhD
From the Medical College of Wisconsin (B.L.B., M.A.M., L.D.N.), Milwaukee; University of Washington (N.T., J.K.B.), Seattle; University of Pittsburgh Medical Center (D.O.O.), PA; University of California San Diego (M.S.), La Jolla; Massachusetts General Hospital and Harvard Medical School (Y.G.B., J.T.G.), Boston; The Ohio State University Wexner Medical Center (J.C.), Columbus; University of Pennsylvania (R.D.-A.), Philadelphia; and University of California, San Francisco (G.T.M.).
Disclosure
Scientific Advisory Boards:
1.
Wave Neuro--DSMB member<br>Bristol-Myer--DSMB member<br>TauRx--DSMB member<br>Novartis--DSMB member
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
University of Southern California<br>TBI Solutions<br>Neurotrauma Sciences<br>Medical College of Wisconsin
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Abbott Point of Care
Research Support, Government Entities:
1.
NIH/NINDS, 1U01 NS086090, multiple PI, 2012-2021<br>DoD, W81XWH-14-2-0176, investigator, 2014-2023<br>NIH/NINDS, R01 NS080648, multiple PI, 2012-2019<br>NIH/NINDS, R01 NS091618, investigator, 2015-2025<br>DoD, W81XWH-18-2-0042, investigator, 2018-2021<br>NIH/NINDS, U01 NS099084-01, investigator, 2018-2023<br>DoD, W81XWH-15-9-0001, investigator, 2018-2023<br>NIH/NINDS, R01 NS110856, investigator, 2019-2024<br>NIH/NICHD, FIC R01-HD106273, MPI, 2021-2026
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Jason K. Barber, MS
From the Medical College of Wisconsin (B.L.B., M.A.M., L.D.N.), Milwaukee; University of Washington (N.T., J.K.B.), Seattle; University of Pittsburgh Medical Center (D.O.O.), PA; University of California San Diego (M.S.), La Jolla; Massachusetts General Hospital and Harvard Medical School (Y.G.B., J.T.G.), Boston; The Ohio State University Wexner Medical Center (J.C.), Columbus; University of Pennsylvania (R.D.-A.), Philadelphia; and University of California, San Francisco (G.T.M.).
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
David O. Okonkwo, MD, PhD https://orcid.org/0000-0002-7444-2851
From the Medical College of Wisconsin (B.L.B., M.A.M., L.D.N.), Milwaukee; University of Washington (N.T., J.K.B.), Seattle; University of Pittsburgh Medical Center (D.O.O.), PA; University of California San Diego (M.S.), La Jolla; Massachusetts General Hospital and Harvard Medical School (Y.G.B., J.T.G.), Boston; The Ohio State University Wexner Medical Center (J.C.), Columbus; University of Pennsylvania (R.D.-A.), Philadelphia; and University of California, San Francisco (G.T.M.).
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Murray Stein, MD
From the Medical College of Wisconsin (B.L.B., M.A.M., L.D.N.), Milwaukee; University of Washington (N.T., J.K.B.), Seattle; University of Pittsburgh Medical Center (D.O.O.), PA; University of California San Diego (M.S.), La Jolla; Massachusetts General Hospital and Harvard Medical School (Y.G.B., J.T.G.), Boston; The Ohio State University Wexner Medical Center (J.C.), Columbus; University of Pennsylvania (R.D.-A.), Philadelphia; and University of California, San Francisco (G.T.M.).
Disclosure
Scientific Advisory Boards:
1.
Dr. Stein is on the scientific advisory board for the Brain and Behavior Research Foundation and the Anxiety and Depression Association of America.<br>Editorial Boards: <br>Dr. Stein has been paid for his editorial work on Depression and Anxiety (Editor-in-Chief), Biological Psychiatry (Deputy Editor), and UpToDate (Co-Editor-in-Chief for Psychiatry).
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Dr. Stein has in the past 3 years received consulting income from Acadia Pharmaceuticals, Aptinyx, atai Life Sciences, BigHealth, Biogen, Bionomics, Boehringer Ingelheim, EmpowerPharm, Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, NeuroTrauma Sciences, PureTech Health, Sage Therapeutics, Sumitomo Pharma, and Roche/Genentech. He has also received research support from NIH, Department of Veterans Affairs, and the Department of Defense.
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NINDS TRACK-TBI Grant (PI: Manley, G.)
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
Dr. Stein has stock options in Oxeia Biopharmaceuticals and EpiVario.
Legal Proceedings:
1.
Expert witness for Roche/Genetech (unrelated to the present study)
Yelena G. Bodien, PhD
From the Medical College of Wisconsin (B.L.B., M.A.M., L.D.N.), Milwaukee; University of Washington (N.T., J.K.B.), Seattle; University of Pittsburgh Medical Center (D.O.O.), PA; University of California San Diego (M.S.), La Jolla; Massachusetts General Hospital and Harvard Medical School (Y.G.B., J.T.G.), Boston; The Ohio State University Wexner Medical Center (J.C.), Columbus; University of Pennsylvania (R.D.-A.), Philadelphia; and University of California, San Francisco (G.T.M.).
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
The study was funded by National Institute of Neurological Disorders and Stroke <br>(NINDS) grants #U01 NS1365885 and U01 NS114140
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
John Corrigan, PhD
From the Medical College of Wisconsin (B.L.B., M.A.M., L.D.N.), Milwaukee; University of Washington (N.T., J.K.B.), Seattle; University of Pittsburgh Medical Center (D.O.O.), PA; University of California San Diego (M.S.), La Jolla; Massachusetts General Hospital and Harvard Medical School (Y.G.B., J.T.G.), Boston; The Ohio State University Wexner Medical Center (J.C.), Columbus; University of Pennsylvania (R.D.-A.), Philadelphia; and University of California, San Francisco (G.T.M.).
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
Journal of Head Trauma Rehabilitation, Editor-in-Chief, 2007-present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
Rehabilitation Psychology Inc., President, 1983-present
Consultancies:
1.
National Association of State Head Injury Administrators
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) National Institute on Disability Independent Living and Rehabilitation <br>Research<br>(2) National Institutes of Health<br>(3) Patient Centered Outcomes Research Institute<br>(4) Administration on Community Living, DHHS<br>(5) State of Ohio
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ramon Diaz-Arrastia, MD, PhD
From the Medical College of Wisconsin (B.L.B., M.A.M., L.D.N.), Milwaukee; University of Washington (N.T., J.K.B.), Seattle; University of Pittsburgh Medical Center (D.O.O.), PA; University of California San Diego (M.S.), La Jolla; Massachusetts General Hospital and Harvard Medical School (Y.G.B., J.T.G.), Boston; The Ohio State University Wexner Medical Center (J.C.), Columbus; University of Pennsylvania (R.D.-A.), Philadelphia; and University of California, San Francisco (G.T.M.).
Disclosure
Scientific Advisory Boards:
1.
NeuralAnalytics, Inc<br>BrainBox Solutions, Inc<br>MesoScale Discoveries
Gifts:
1.
BrainBox Solutions, Inc.
Funding for Travel or Speaker Honoraria:
1.
BrainBox, Inc
Editorial Boards:
1.
Journal of Neurotrauma<br>Frontiers of Neuroscience
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
BrainBox Solutions, Inc
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH/NINDS U01 NS086090 09/01/2013-08/30/2018 co-PI<br>NIH/NINDSProject Title: &#x0093;Transforming Research and <br>Clinical Knowledge in Traumatic Brain Injury (TRACK TBI)&#x0094;<br><br>DoD/USAMRAA Diaz-Arrastia (Co-PI) (Manley-PI)<br>09/01/2014-<br>08/31/2018<br>Project Title: &#x0093;TBI Endpoints Development (TED)&#x0094;<br><br>NIH/NINDS U01 NS099046 (Diaz-Arrastiaco-PI) 8/1/2018 &#x0096; <br>7/31/20232.4 <br>$32,532,017<br>Project Title: Brain Oxygen Optimization in Severe TBI&#x0097;<br>Phase <br>3 (BOOST-3)<br><br>NIH/NINDS U24 NS107199 (R. Diaz-Arrastia, contact PI)<br>9/1/2018 &#x0096; 8/31/2023<br>Project title: Penn Center for Excellence in Neuroscience <br>Clinical Trials (Penn NeuroNEXT)<br><br>NIH/NINDS U01 NS114140(R.Diaz-Arrastia, PI)<br>12/1/2019 &#x0096; 11/30/2024<br>Project Title: Clinical validation of serum neurofilament <br>light as a biomarker of traumatic axonal injury<br><br>US Dept. of Defense BA170613 (R. Diaz-Arrastia, PI)<br>9/1/2019 &#x0096; 8/30/2023<br>Project Title: Biomarkers of Brain Oxygen Optimization in <br>Severe TBI Trial (Bio-BOOST)<br><br>US Department of Defense EP180013 (R. Diaz-Arrastia, PI)<br>9/1/2019 &#x0096; 8/30/2023<br>Project Title: TRACK-TBI Epileptogenesis Project<br>Stock/Stock Options/Board of Directors Compensation: <br>Neural Analytics, Inc<br>BrainBox Solutions, Inc<br>Stock/Stock Options, Medical Equipment & Materials: <br>Neural Analytics, Inc
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Joseph T. Giacino, PhD
From the Medical College of Wisconsin (B.L.B., M.A.M., L.D.N.), Milwaukee; University of Washington (N.T., J.K.B.), Seattle; University of Pittsburgh Medical Center (D.O.O.), PA; University of California San Diego (M.S.), La Jolla; Massachusetts General Hospital and Harvard Medical School (Y.G.B., J.T.G.), Boston; The Ohio State University Wexner Medical Center (J.C.), Columbus; University of Pennsylvania (R.D.-A.), Philadelphia; and University of California, San Francisco (G.T.M.).
Disclosure
Scientific Advisory Boards:
1.
Traumatic Brain Injury Model Systems National Data and <br>Statistical Center (federal agency)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
Journal of Head Trauma Rehabilitation, Editorial Board, <br>2002-Present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1) U.S. Department of Defense, Co-Investigator, W81XWH-11-<br>2-0210, 2011-2013 (NCE 2014-2017), Co-Investigator; W81XWH-<br>08-2-0159, 2011-2014, Co-Investigator; W81XWH-14-2-0176, <br>2014-2019, Co-PI <br>2) National Institute on Disability and Rehabilitation <br>Research, 90DPTB0011, 2017-2022, PI; 90DPCP0008, 2020-2025, <br>PI <br>4) National Institute of Neurological Disorders and Stroke, <br>UH3NS095554, 2015-2020, Co-PI; UG3 NS117844-01, 2021-2028, <br>Site PI
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
1) James S. McDonnell Foundation<br>2) The Barbara Epstein Foundation, Inc
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Michael A. McCrea, PhD
From the Medical College of Wisconsin (B.L.B., M.A.M., L.D.N.), Milwaukee; University of Washington (N.T., J.K.B.), Seattle; University of Pittsburgh Medical Center (D.O.O.), PA; University of California San Diego (M.S.), La Jolla; Massachusetts General Hospital and Harvard Medical School (Y.G.B., J.T.G.), Boston; The Ohio State University Wexner Medical Center (J.C.), Columbus; University of Pennsylvania (R.D.-A.), Philadelphia; and University of California, San Francisco (G.T.M.).
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Travel support and honoraria for professional speaking.
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
MTBI and PCS: New Evidence Base for Diagnosis and Treatment<br><br><br><br><br><br><br><br><br><br><br><br><br><br><br><br>Management. Oxford University Press
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Clinical consultant - Green Bay Packers Football Club<br><br><br><br><br><br><br><br>Consultant, Neurotrauma Sciences, Inc.
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Research funding to Medical College of Wisconsin from NCAA, NFL, Abbott <br><br><br><br>Laboratories.
Research Support, Government Entities:
1.
Research funding to Medical College of Wisconsin from NIH, U.S. Department of <br><br><br><br>Defense, VA, CDC
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
Conducted medical legal evaluations
Geoffrey T. Manley, MD, PhD https://orcid.org/0000-0002-0926-3128
From the Medical College of Wisconsin (B.L.B., M.A.M., L.D.N.), Milwaukee; University of Washington (N.T., J.K.B.), Seattle; University of Pittsburgh Medical Center (D.O.O.), PA; University of California San Diego (M.S.), La Jolla; Massachusetts General Hospital and Harvard Medical School (Y.G.B., J.T.G.), Boston; The Ohio State University Wexner Medical Center (J.C.), Columbus; University of Pennsylvania (R.D.-A.), Philadelphia; and University of California, San Francisco (G.T.M.).
Disclosure
Scientific Advisory Boards:
1.
None
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
One Mind has provided funding for TRACK-TBI patients stipends and support to clinical sites. An unrestricted gift from the NFL to the UCSF Foundation to support research efforts of the TRACK-TBI NETWORK was received. Dr. Manley has also received funding from NeuroTruama Sciences LLC to support TRACK-TBI data curation efforts. And Abbott Laboratories has provided funding for add-in TRACK-TBI clinical studies.
Research Support, Government Entities:
1.
Dr. Manley discloses grants from the United States Department of Defense &#x0096; TBI Endpoints Development Initiative (Grant #W81XWH-14-2-0176), TRACK-TBI Precision Medicine (Grant # W81XWH-18-2-0042), and TRACK-TBI NETWORK (Grant # W81XWH-15-9-0001); NIH-NINDS &#x0096; TRACK-TBI (Grant #U01NS086090); and the National Football League (NFL) Scientific Advisory Board &#x0096; TRACK-TBI LONGITUDINAL. United States Department of Energy supports Dr. Manley for a precision medicine collaboration.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Lindsay D. Nelson, PhD, MPH
From the Medical College of Wisconsin (B.L.B., M.A.M., L.D.N.), Milwaukee; University of Washington (N.T., J.K.B.), Seattle; University of Pittsburgh Medical Center (D.O.O.), PA; University of California San Diego (M.S.), La Jolla; Massachusetts General Hospital and Harvard Medical School (Y.G.B., J.T.G.), Boston; The Ohio State University Wexner Medical Center (J.C.), Columbus; University of Pennsylvania (R.D.-A.), Philadelphia; and University of California, San Francisco (G.T.M.).
Disclosure
Scientific Advisory Boards:
1.
(1) National Institute of Neurological Disorders and Stroke, <br>(2) Department of Defense, (3) Medical Technology Enterprise <br>Consortium, (4) Centers for Disease Control and Prevention, <br>(5) Medical College of Wisconsin Advancing a Healthier <br>Wisconsin Endowment
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
None
Editorial Boards:
1.
I served as a guest editor of a special issue of Biological <br>Psychiatry (no compensation; 2021)
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Work as an independent consultant on a research project <br>funded by the National Institute of Neurological Disorders and <br>Stroke, (2) Expert panel member for work with the American <br>College of Emergency Physicians funded by Abbott (2023)
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) National Institute of Neurological Disorders and Stroke <br>(NINDS), 5R01NS110856, PI, 2019-present, (2) NINDS, <br>1R01NS102225, Co-I, 2017-present, (3) NINDS, R21NS118169, <br>Co-I, 2020-present, (4) Medical Technology Enterprise <br>Consortium, W81XWH-15-9-001, Co-I, 2018-present, (5) DoD <br>Army Medical Research Acquisition, W81XWH-14-2-0176, Co-I, <br>2014-present, (6) NINDS, 1R01NS110600-01, Co-I, 2019-<br>present, (7) Centers for Disease Control and Prevention, <br>U01CE002944-01-02, 2018-present, (8) Uniformed Services <br>University of the Health Sciences, HU0001-18-2-0008, Co-I, <br>2019-present, (9) Department of Defense, W81XWH-17-1-0019, <br>CO-I, 2018-2021, (10) DoD Army Medical Research Acquisition, <br>W81XWH-18-2-0047, Co-I, 2018-2021, (11) Medical College of <br>Wisconsin Advancing a Healthier Wisconsin Endowment, (no <br>award number), PI, 2019-2021, (12) NINDS, 1R21NS099789, Co-<br>I, 2017-2020, (13) National Football League, NFL 7-11-2016, <br>2016-2020, (14) NINDS, 1R03NS100691, PI, 2017-2020.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
None
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
for TRACK-TBI Investigators
From the Medical College of Wisconsin (B.L.B., M.A.M., L.D.N.), Milwaukee; University of Washington (N.T., J.K.B.), Seattle; University of Pittsburgh Medical Center (D.O.O.), PA; University of California San Diego (M.S.), La Jolla; Massachusetts General Hospital and Harvard Medical School (Y.G.B., J.T.G.), Boston; The Ohio State University Wexner Medical Center (J.C.), Columbus; University of Pennsylvania (R.D.-A.), Philadelphia; and University of California, San Francisco (G.T.M.).

Notes

Correspondence Dr. Brett [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Coinvestigators are listed in Appendix 2 at the end of the article.
Submitted and externally peer reviewed. The handling editor was Associate Editor Rebecca Burch, MD.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. The critical importance of time in the management of acute neurological injuries, Current Opinion in Critical Care, 31, 2, (109-111), (2025).https://doi.org/10.1097/MCC.0000000000001256
    Crossref
  2. Natural history of recovery and long-term outcome in critically ill patients with brain injury, Current Opinion in Critical Care, 31, 2, (162-169), (2025).https://doi.org/10.1097/MCC.0000000000001242
    Crossref
  3. Timing of neuroprognostication in the ICU, Current Opinion in Critical Care, 31, 2, (155-161), (2025).https://doi.org/10.1097/MCC.0000000000001241
    Crossref
  4. Cell-Specific Gene Expressions Underlie Selective White Matter Loss Vulnerability in Mild Traumatic Brain Injury, Journal of Neurotrauma, 42, 1-2, (118-130), (2025).https://doi.org/10.1089/neu.2024.0022
    Crossref
  5. Exploring the challenges of avoiding collisions with virtual pedestrians using a dual-task paradigm in individuals with chronic moderate to severe traumatic brain injury, Journal of NeuroEngineering and Rehabilitation, 21, 1, (2024).https://doi.org/10.1186/s12984-024-01378-x
    Crossref
  6. Evaluating the complex systems approach to persisting post-concussion symptoms, Theory & Psychology, 35, 1, (17-39), (2024).https://doi.org/10.1177/09593543241287749
    Crossref
  7. Predictive Utility of Diffusion MRI After Mild Traumatic Brain Injury in Civilian Populations: A Systematic Review, The Journal of Neuropsychiatry and Clinical Neurosciences, 36, 3, (187-196), (2024).https://doi.org/10.1176/appi.neuropsych.20230122
    Crossref
  8. Cognitive Performance is Associated With 1-Year Participation and Life Satisfaction Outcomes: A Traumatic Brain Injury Model Systems Study, Journal of Head Trauma Rehabilitation, (2024).https://doi.org/10.1097/HTR.0000000000000997
    Crossref
  9. Long-term pituitary function and functional and patient-reported outcomes in severe acquired brain injury, European Journal of Endocrinology, 190, 5, (382-390), (2024).https://doi.org/10.1093/ejendo/lvae047
    Crossref
  10. Plasma biomarkers in chronic single moderate/severe traumatic brain injury, Brain, 147, 11, (3641-3642), (2024).https://doi.org/10.1093/brain/awae318
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Short Form

Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share